×

Amicus Therapeutics Announces Posters and Presentations at Lysosomal Disease Network WORLD Symposium

CRANBURY, N.J., Feb. 7, 2013 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced that 2 oral presentations and 5 posters related to its investigational pharmacological chaperones will be included at the 9th Annual Lysosomal Disease Network WORLD Symposium (LDN WORLD), to be held February 13-15, 2013 in Orlando, FL. The Company will host a conference call and live audio/visual webcast on Friday, February 15, 2013 at 11:30am ET to highlight the data presented at LDN WORLD.

Posters: Wednesday, February 13, 2013, 4:30-6:30pm ET and Thursday, February 14, 2013, 4:30-6:00pm ET

A Phase 2a Study to Investigate the Effect of a Single Dose of Migalastat HCl, a Pharmacological Chaperone, on Agalsidase Activity in Subjects with Fabry Disease – D. Warnock, D. Bichet, M. Holida, O. Goker-Alpan, K. Nicholls, M. Thomas, F. Eyskens, S. Shankar, G. Linthorst, M. Dasouki, F. K. Johnson, P. Boudes

A Phase 2a Study to Investigate Drug-Drug Interactions between Escalating Doses of AT2220 (Duvoglustat Hydrochloride) and Acid Alfa-Glucosidase in Subjects with Pompe Disease – P. Kishnani, M. Tarnopolsky, K. Sivakumar, M. Roberts, B. Byrne, O. Goker-Alpan, K. Guter, M. Pervaiz, M. Dasouki, T. Mozaffar, E. Finanger, F. Johnson, P. Boudes

Exploring the Use of a Co-Formulated Pharmacological Chaperone AT2220 with Recombinant Human Acid Alfa-Glucosidase for Pompe Disease – R. Khanna, S. Xu, Y. Lun, R. Soska, J. Feng, M. Frascella, A. Garcia, J. Flanagan, D. J. Lockhart, K. Valenzano

High Incidence of GLA Variants In A Non-Selected Heart Disease Patient Population Suggests That The Fabry Trait Is A Common Cardiovascular Genetic Risk Factor - R. Schiffman, S. Forni, C. Swift, X. Wu, D. J. Lockhart, M. Chee, T. Kitaoka, E. Chudin, S. Pond, N.H. McNeill, K. Sims, E.R. Benjamin, L. Sweetman

The Origins of Glucosylsphingosine in Gaucher Disease – J. Flanagan, B. Ranes, N. Brignol, R. Hamler, S.W. Clark

Oral Platform Presentations:

A Phase 2a Study to Investigate Drug-Drug Interactions between Escalating Doses of AT2220 (Duvoglustat Hydrochloride) and Acid Alfa-Glucosidase in Subjects with Pompe Disease – P. Kishnani, M. Tarnopolsky, K. Sivakumar, M. Roberts, B. Byrne, O. Goker-Alpan, K. Guter, M. Pervaiz, M. Dasouki, T. Mozaffar, E. Finanger, F. Johnson, P. Boudes

  • Friday, February 15, 2013, 9:15-9:30am ET (Mark Tarnopolsky, McMaster University)

Phase 3 Study of Migalastat HCl for Fabry Disease: Stage 1 Results. – K. Nicholls, D.P. Germain, C. Feliciani, S. Shankar, F. Ezgu, S.G. Janmohamed, S.M. Laing, R. Schroyer, A.C. Bragat, S. Sitaraman, P. Boudes

  • Friday, February 15, 2013, 10:30-10:45am ET (Fatih Ezgu, Gazi University)

Conference Call and Webcast:

John F. Crowley, Chairman and Chief Executive Officer, and members of the Amicus executive team will host a conference call and live audio/visual webcast on Friday, February 15, 2013 at 11:30am ET to discuss the data presented at LDN WORLD.

Interested participants and investors may access the conference call at 11:30 a.m. ET by dialing 877-303-5859 (U.S./Canada) or 678-224-7784 (international). A live audio webcast can also be accessed via the Investors section of the Amicus Therapeutics corporate web site at http://ir.amicustherapeutics.com/events.cfm, and will be archived for 30 days. The slide presentation for the conference call/webcast will also be available at http://ir.amicustherapeutics.com/events.cfm. Web participants are encouraged to go to the web site 15 minutes prior to the start of the call to register, download and install any necessary software.

A telephonic replay of the call will be available for seven days beginning at 2:30 p.m. ET on February 15, 2013. Access numbers for this replay are 855-859-2056 (U.S./Canada) and 404-537-3406 (international); participant code 97505816.

About Amicus Therapeutics

Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the forefront of therapies for rare and orphan diseases. The Company is developing orally-administered, small molecule drugs called pharmacological chaperones, a novel, first-in-class approach to treating a broad range of human genetic diseases. Amicus' late-stage programs for lysosomal storage disorders include migalastat HCl monotherapy in Phase 3 for Fabry disease; migalastat HCl co-administered with enzyme replacement therapy (ERT) in Phase 2 for Fabry disease; and AT2220 co-administered with ERT in Phase 2 for Pompe disease.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to clinical development of Amicus' candidate drug products and the timing and reporting of results from clinical trials evaluating Amicus' candidate drug products. Words such as, but not limited to, "look forward to," "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "should" and "could," and similar expressions or words identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. The inclusion of forward-looking statements should not be regarded as a representation by Amicus that any of its plans will be achieved. Any or all of the forward-looking statements in this press release may turn out to be wrong. They can be affected by inaccurate assumptions Amicus might make or by known or unknown risks and uncertainties. For example, with respect to statements regarding the goals, progress, timing and outcomes of discussions with regulatory authorities and the potential goals, progress, timing and results of clinical trials, actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the business of Amicus, including, without limitation: the potential that results of clinical or pre-clinical studies indicate that the product candidates are unsafe or ineffective; the potential that it may be difficult to enroll patients in our clinical trials; the potential that regulatory authorities may not grant or may delay approval for our product candidates; the potential that preclinical and clinical studies could be delayed because we identify serious side effects or other safety issues; the potential that we will need additional funding to complete all of our studies and, our dependence on third parties in the conduct of our clinical studies. Further, the results of earlier preclinical studies and/or clinical trials may not be predictive of future results. In addition, all forward looking statements are subject to other risks detailed in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2012. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Amicus undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

FOLD–G

CONTACT: Investors/Media: Sara Pellegrino spellegrino@amicusrx.com (609) 662-5044Source:Amicus Therapeutics, Inc.